Targeted drug discovery for Alzheimer disease:
abridged secondary publication
AML Chan1, L Baum2, RCC Chang1, JA Esteban3, ZX Lin4, YH Wong5, WH Yung1
1School of Biomedical Sciences, The Chinese University of Hong Kong
2School of Pharmacy, The Chinese University of Hong Kong
3Department of Molecular Neurobiology, Centro de Biología Molecular 'Severo Ochoa', Consejo Superior de Investigaciones Científicas (CSIC), Spain
4School of Chinese Medicine, The Chinese University of Hong Kong
5Division of Life Science, The Hong Kong University of Science and Technology
1. We identify a small molecule, ZL006, that
possesses therapeutic effects by alleviating
memory deficits in a mouse model of Alzheimer
disease.
2. The therapeutic effects of ZL006 in enhancing learning and memory are likely due to its ability in blocking PTEN-mediated pathological events in synapses.
3. The mechanism of action of ZL006 is likely due to restoration of synaptic function but not by promoting neuronal survival.
4. ZL006 has the potential in treating early stage Alzheimer disease.
2. The therapeutic effects of ZL006 in enhancing learning and memory are likely due to its ability in blocking PTEN-mediated pathological events in synapses.
3. The mechanism of action of ZL006 is likely due to restoration of synaptic function but not by promoting neuronal survival.
4. ZL006 has the potential in treating early stage Alzheimer disease.